BR9607169A - Use of meletonin and pharmaceutical formulation for use in the treatment of a multiple drug addict - Google Patents

Use of meletonin and pharmaceutical formulation for use in the treatment of a multiple drug addict

Info

Publication number
BR9607169A
BR9607169A BR9607169A BR9607169A BR9607169A BR 9607169 A BR9607169 A BR 9607169A BR 9607169 A BR9607169 A BR 9607169A BR 9607169 A BR9607169 A BR 9607169A BR 9607169 A BR9607169 A BR 9607169A
Authority
BR
Brazil
Prior art keywords
meletonin
treatment
pharmaceutical formulation
multiple drug
drug addict
Prior art date
Application number
BR9607169A
Other languages
Portuguese (pt)
Inventor
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of BR9607169A publication Critical patent/BR9607169A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR9607169A 1995-02-01 1996-01-29 Use of meletonin and pharmaceutical formulation for use in the treatment of a multiple drug addict BR9607169A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies
PCT/IB1996/000082 WO1996023496A1 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Publications (1)

Publication Number Publication Date
BR9607169A true BR9607169A (en) 1997-11-11

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9607169A BR9607169A (en) 1995-02-01 1996-01-29 Use of meletonin and pharmaceutical formulation for use in the treatment of a multiple drug addict

Country Status (22)

Country Link
JP (1) JP4516159B2 (en)
CN (1) CN1083263C (en)
AT (1) AT408188B (en)
AU (1) AU695366B2 (en)
BG (1) BG62876B1 (en)
BR (1) BR9607169A (en)
CZ (1) CZ291349B6 (en)
DK (1) DK176081B1 (en)
EE (1) EE03384B1 (en)
FI (1) FI119586B (en)
IS (1) IS1980B (en)
LU (1) LU90118B1 (en)
LV (1) LV11940B (en)
MD (1) MD1716C2 (en)
NO (1) NO312814B1 (en)
NZ (1) NZ298878A (en)
PL (1) PL183148B1 (en)
SI (1) SI9620022A (en)
SK (1) SK284521B6 (en)
TR (1) TR199700723T1 (en)
TW (1) TW483757B (en)
WO (1) WO1996023496A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0016918A (en) 2000-01-05 2004-03-23 Neurim Pharma 1991 Process and formulation for treating antihypertensive resistance and related conditions
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Composition for treating insomnia
CA2861111C (en) 2012-01-26 2021-11-23 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
ES2805376T3 (en) 2012-12-18 2021-02-11 Vanda Pharmaceuticals Inc Tasimelteon for treating circadian rhythm disorders
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
EP3777842A1 (en) * 2016-10-31 2021-02-17 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229490T2 (en) * 1991-05-09 2000-02-17 Neurim Pharma 1991 Medicines containing melatonin
IT1251544B (en) * 1991-05-13 1995-05-17 Gabriele Biella PHARMACEUTICAL COMPOSITIONS ACTIVE IN THE THERAPY OF SLEEP DISORDERS INCLUDING MELATONIN OR A DERIVATIVE IN ASSOCIATION WITH A BENZODIAZEPINE DERIVATIVE

Also Published As

Publication number Publication date
PL183148B1 (en) 2002-05-31
MD970254A (en) 1999-05-31
DK176081B1 (en) 2006-04-18
NZ298878A (en) 1999-05-28
SK284521B6 (en) 2005-05-05
BG62876B1 (en) 2000-10-31
SK103097A3 (en) 1998-01-14
AU4457496A (en) 1996-08-21
CZ240597A3 (en) 1998-01-14
LV11940B (en) 1998-05-20
AU695366B2 (en) 1998-08-13
SI9620022A (en) 1998-10-31
LU90118B1 (en) 1997-11-13
IS1980B (en) 2005-01-14
ATA901396A (en) 2001-02-15
CZ291349B6 (en) 2003-02-12
TR199700723T1 (en) 1998-02-21
CN1172431A (en) 1998-02-04
CN1083263C (en) 2002-04-24
IS4532A (en) 1997-07-25
FI119586B (en) 2009-01-15
MD1716B2 (en) 2001-08-31
JP4516159B2 (en) 2010-08-04
NO312814B1 (en) 2002-07-08
FI973185A (en) 1997-09-30
PL321630A1 (en) 1997-12-08
NO973531D0 (en) 1997-07-31
TW483757B (en) 2002-04-21
BG101803A (en) 1998-04-30
EE03384B1 (en) 2001-04-16
AT408188B (en) 2001-09-25
NO973531L (en) 1997-09-30
LV11940A (en) 1998-01-20
EE9700166A (en) 1998-02-16
WO1996023496A1 (en) 1996-08-08
DK89697A (en) 1997-07-30
FI973185A0 (en) 1997-07-31
MD1716C2 (en) 2002-02-28
JPH10513177A (en) 1998-12-15
MX9705856A (en) 1998-07-31

Similar Documents

Publication Publication Date Title
BR9510510A (en) Pharmaceutical aerosol formulation using it and processes for manufacturing it to treat a patient in need of therapy
BR9610248A (en) Compound pharmaceutical composition processes for the treatment of pain and for the preparation of a compound and use of the compound
PT1037667E (en) PHARMACEUTICAL FORMULATIONS IN HIDROGEL DEVICES AND METHODS FOR ADMINISTRATION OF DRUGS
BR9510422A (en) Powder formulation for administration of medically useful polypeptides use of powder and processes for manufacturing the formulation and for treating a patient in need of therapy
DE69525148T2 (en) PHARMACEUTICAL FORMULATION
KR950703566A (en) Thienodiazepine compound and its pharmaceutical use [THIENODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF]
BR9703624A (en) Combination pharmaceutical formulation process for the treatment of depression in an animal use of mirtazapine use of one or more srri's and packaging
BR9602915A (en) Medicines use and pharmaceutical formulation
CY2007001I1 (en) MEDICINAL PREPARATION FOR USE IN THE TREATMENT OF DIABETES
DE69618587D1 (en) CHINAZOLINE AND PHARMACEUTICAL COMPOSITIONS
BR9510501A (en) Aerosol formulation using it and processes for manufacturing it and for treating a patient in need of therapy
FI953479A0 (en) 1-Arylpyrimidine derivatives and their pharmaceutical use
BR9709267A (en) Preparation of monoclonal antibody for administration to a human pharmaceutical formulation use of a monoclonal antibody preparation and process for the manufacture of a monoclonal antibody preparation
EE04021B1 (en) 7α- (-aminoalkyl) oestratrienes, process for their preparation, pharmaceutical preparations containing 7α- (-aminoalkyl) oestratrienes and their use in the manufacture of medicaments
DE69622735D1 (en) LYOPHILIZED STABLE PHARMACEUTICAL FORMULATION
DE69600065T2 (en) Dermatological and / or pharmaceutical preparation, its manufacture and use
BR9510302A (en) Controlled-release pharmaceutical dosage form Method for symptomatic treatment of cough Method for preparing a controlled-release pharmaceutical dosage form composition for use in the symptomatic treatment of cough and application of a controlled-release moguistein dosage form
NO961136D0 (en) Pharmaceutical formulation basis for nano-suspensions
PT1183029E (en) PHARMACEUTICAL PREPARATION CONTAINING THE ACTIVE DIAMORPHINE PRINCIPLE AND ITS USE IN A PROCESS FOR THE TREATMENT OF OPIACEAL DEPENDENCE
BR9607851B1 (en) combination and pharmaceutical formulation.
ATE288419T1 (en) ALPHA-ARYL-N-ALKYLNITRONES AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME
EE9600172A (en) Purin-6-one derivatives, their preparation method, use in the preparation of medicaments and medicaments
DE59607535D1 (en) COSMETIC AND / OR PHARMACEUTICAL PREPARATIONS
EE9900086A (en) Benzamidine Derivatives and Their Use as LTB-4 Antagonist Drugs
EE9600139A (en) Pharmaceutical preparations and drugs for the prevention and treatment of endothelial dysfunctions

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO COM BASE NO ART. 229-A DA LEI 10.196 DE 14/02/2001.